Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATN-224 with Temozolomide in Advanced Melanoma
NCT00383851Phase 2Unknown
- Sponsor
- Attenuon LLC
- Start
- Sep 2006
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atn-224 in melanoma and Uveal melanoma (UM) (2 arms), sponsored by Attenuon LLC. Primary endpoints: 24-week Progression-Free Survival and Safety and Adverse Events. Status: unknown.
02
Drugs
atn-224
03
Conditions
melanomaUveal melanoma (UM)
Beyond the preview
Go deeper on NCT00383851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383851.